These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7395819)

  • 1. Chromogenic substrate (S-2238) prothrombin assay in prothrombin deficiencies and abnormalities. Lack of identity with clotting assays in congenital dysprothrombinemias.
    Girolami A; Patrassi G; Toffanin F; Saggin L
    Am J Clin Pathol; 1980 Jul; 74(1):83-7. PubMed ID: 7395819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital deficiencies and abnormalities of prothrombin.
    Girolami A; Scarano L; Saggiorato G; Girolami B; Bertomoro A; Marchiori A
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):557-69. PubMed ID: 9863703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor X assays using chromogenic substrate S-2222.
    Girolami A; Saggin L; Boeri G
    Am J Clin Pathol; 1980 Mar; 73(3):400-2. PubMed ID: 7361721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital bleeding disorders of the vitamin K-dependent clotting factors.
    Girolami A; Scandellari R; Scapin M; Vettore S
    Vitam Horm; 2008; 78():281-374. PubMed ID: 18374200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normotest--thrombotest discrepancy in congenital coagulation disorders of the prothrombin complex and in coumarin-treated patients: a nonspecific phenomenon.
    Girolami A; Brunetti A; Patrassi GM
    Am J Clin Pathol; 1977 Jan; 67(1):57-60. PubMed ID: 831455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations are no substitutes for clotting, chromogenic and immunological assays in patients with congenital prothrombin deficiency.
    Girolami A; Scarparo P; Allemand E
    Am J Hematol; 2008 Jun; 83(6):518; author reply 518-9. PubMed ID: 18306360
    [No Abstract]   [Full Text] [Related]  

  • 7. Taipan viper venom and chromogenic substrate (chromozym Th). Prothrombin assay. No sensitivity to coumarin-induced prothrombin.
    Girolami A; Petrassi G; Cella G; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):822-30. PubMed ID: 6176507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Constitutional and acquired dysprothrombinemias].
    Josso F; Lavergne JM; Soulier JP
    Nouv Rev Fr Hematol; 1970; 10(5):633-44. PubMed ID: 4250286
    [No Abstract]   [Full Text] [Related]  

  • 9. Prothrombin antigen evaluation by means of laser nephelometry in health and disease.
    Girolami A; Saggin L; Ruffato G; Sticchi A; Capellato G
    Am J Clin Pathol; 1982 Nov; 78(5):773-6. PubMed ID: 7137121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
    Girolami A; Brunetti A; Patrassi G; Cafiero F
    Blut; 1975 Nov; 31(5):291-8. PubMed ID: 811288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogenic substrate (S-2222) factor X assays in the follow-up of coumarin treated patients. No advantage over prothrombin time and/or thrombotest.
    Girolami A; Saggin L; Gazzetta R; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):610-6. PubMed ID: 6170557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The "echis carinatus venom" prothrombin assay in coumarin treated patients. A comparison with one-stage and immunological assays.
    Girolami A; Brunetti A; Patrassi G; Borsato N
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(5):746-57. PubMed ID: 64416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin level in coumarin-treated patients. A peculiar effect observed in a one-stage system using certain substrates.
    Girolami A; Bareggi G; Cella G; Patrassi G
    Am J Clin Pathol; 1974 May; 61(5):654-61. PubMed ID: 4857077
    [No Abstract]   [Full Text] [Related]  

  • 14. Prothrombin Segovia: a new congenital abnormality of prothrombin.
    Rocha E; Paramo JA; Bascones C; Fisac PR; Cuesta B; Fernandez J
    Scand J Haematol; 1986 May; 36(5):444-9. PubMed ID: 3090681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin Habana: a new dysfunctional molecule of human prothrombin associated with a true prothrombin deficiency.
    Rubio R; Almagro D; Cruz A; Corral JF
    Br J Haematol; 1983 Aug; 54(4):553-60. PubMed ID: 6409139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples.
    Zhao KN; Dimeski G; de Jersey J; Johnson LA; Grant M; Masci PP; Lavin MF
    Clin Chem Lab Med; 2019 Mar; 57(4):483-497. PubMed ID: 30267622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital factor II deficiency: moroccan cases.
    Imane S; Laalej Z; Faez S; Oukkache B
    Int J Lab Hematol; 2013 Aug; 35(4):416-20. PubMed ID: 23190616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation.
    Girolami A; Cosi E; Ferrari S; Girolami B
    J Thromb Thrombolysis; 2018 Jan; 45(1):135-141. PubMed ID: 29063359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COUMARIN THERAPY. PROTHROMBIN ACTIVITY AFTER TERMINATION OF TREATMENT.
    REILLY EB; GOODMAN JR; WARNER GF
    Calif Med; 1963 Oct; 99(4):234-5. PubMed ID: 14051485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.